Cognition Therapeutics, Inc. (CGTX)
NASDAQ: CGTX · IEX Real-Time Price · USD
1.960
+0.020 (1.03%)
May 17, 2024, 4:00 PM EDT - Market closed
Company Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.
The company was incorporated in 2007 and is headquartered in Purchase, New York.
Cognition Therapeutics, Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Oct 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Ms. Lisa Ricciardi |
Contact Details
Address: 2403 Sidney Street, Suite 261 Pittsburgh, Pennsylvania 15203 United States | |
| Phone | 412-481-2210 |
| Website | cogrx.com |
Stock Details
| Ticker Symbol | CGTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001455365 |
| CUSIP Number | 19243B102 |
| ISIN Number | US19243B1026 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Lisa Ricciardi | Chief Executive Officer, President and Director |
| Dr. Anthony O. Caggiano M.D., Ph.D. | Chief Medical Officer and Head of Research & Development |
| John Brendan Doyle | Chief Financial Officer |
| Dr. Steven A. Weissman Ph.D. | Vice President and Head of CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 26, 2024 | 10-K | Annual Report |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 13, 2024 | 8-K | Current Report |
| Mar 13, 2024 | 424B5 | Filing |